Bradley W G, Hudgson P, Foster J B, Newell D J
Br Med J. 1968 Aug 31;3(5617):531-3. doi: 10.1136/bmj.3.5617.531.
A double-blind cross-over trial of a micronized preparation of flumedroxone, an oral progestogen derivative, and a placebo was undertaken to determine whether this drug had prophylactic value in migraine. No benefit was found in males, or in females with no history of menstrual exacerbation of migraine. In women whose migraine was worse around the time of menstruation flumedroxone resulted in statistically fewer headaches of less severity.With the dose used in this trial (micronized flumedroxone 10 mg. t.d.s.) side-effects were frequent, the commonest being polymenorrhagia, which occurred in half the women of reproductive age.
进行了一项双盲交叉试验,以研究口服孕激素衍生物微粉化氟美罗酮制剂和安慰剂,确定该药物对偏头痛是否具有预防作用。结果发现,该药物对男性以及无月经性偏头痛加重病史的女性没有益处。对于经期偏头痛加重的女性,氟美罗酮在统计学上使头痛次数减少且程度减轻。在本试验所使用的剂量(微粉化氟美罗酮10毫克,每日三次)下,副作用频繁出现,最常见的是月经过多,发生在一半的育龄女性中。